M&A Deal Summary

Viva Biotech Acquires Zhejiang Langhua Pharmaceutical

On August 9, 2020, Viva Biotech acquired life science company Zhejiang Langhua Pharmaceutical for 2.8B HKD

Acquisition Highlights
  • This is Viva Biotech’s 1st transaction in the Life Science sector.
  • This is Viva Biotech’s largest (disclosed) transaction.
  • This is Viva Biotech’s 1st transaction in China.

M&A Deal Summary
Date 2020-08-09
Target Zhejiang Langhua Pharmaceutical
Sector Life Science
Buyer(s) Viva Biotech
Deal Type Add-on Acquisition
Deal Value 2.8B HKD

Target

Zhejiang Langhua Pharmaceutical

Zhejiang, China
Zhejiang Langhua Pharmaceutical Co., Ltd is a comprehensive manufacturing enterprises focusing on API and intermediates production and CDMO projects. Zhejiang Langhua Pharmaceutical was founded in 1996 and is based in Zhejiang, China.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Viva Biotech

Hong Kong, China
Category Company
Sector Life Science
DESCRIPTION

Viva Biotech (Shanghai) Co., Ltd. is structure-based, integrated drug discovery platform, providing structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their preclinical stage innovative drug development. Viva Biotech (Shanghai) is based in Hong Kong.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (China) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-15 Totient

Cambridge, Massachusetts, United States

Totient is a discovery company harnessing human immune responses to identify novel antibodies and their therapeutic targets. Totient reconstructs antibodies from patients experiencing exceptional immune responses. Totient was founded in 2017 and is based in Cambridge, Massachusetts.

Sell -
Mergr

Product

Company

Legal